Hematological Disorders

Halozyme and Incyte sign licence agreement for INCA033989 formulations

Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin (mutCALR), in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs).

Takeda and Indonesia partner on plasma-derived therapies

Takeda and the Indonesian Government have announced a multi-phased collaboration to strengthen the country’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs).

FDA gives approval to Viatris for Iron Sucrose Injection

The US Food and Drug Administration (FDA) has approved Viatris, a global healthcare company’s Iron Sucrose Injection for treating iron deficiency anaemia (IDA) in adults and children aged two and older with chronic kidney disease (CKD).

Health Canada authorises Roche’s PiaSky for PNH

Roche Canada has received Health Canada’s authorisation for PiaSky (crovalimab for injection), to treat paroxysmal nocturnal haemoglobinuria (PNH).

FDA grants priority review for AstraZeneca’s Calquence sNDA

The US Food and Drug Administration (FDA) has accepted and granted priority review to AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

Pfizer and Abu Dhabi partner to boost sickle cell disease research

The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle cell disease (SCD).

FDA grants orphan drug designation for Disc’s PV treatment

The US Food and Drug Administration (FDA) has granted orphan drug designation for clinical-stage biopharmaceutical company Disc Medicine’s investigational therapy, DISC-3405, for the treatment of polycythemia vera (PV).

Agios and Alnylam sign agreement for siRNA candidate

Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).

Takeda submits New Drug Application for lanadelumab in Japan

Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.